ReviewBMC neurology2026
Exploring a possible shared pathophysiology in co-occurrence of multiple sclerosis and Hodgkin lymphoma: a case report and review of literature.
Review in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMultiple sclerosis (MS) and Hodgkin lymphoma (HL) share common epidemiology, genetics, and immunological factors. We report a case of a woman who presented with neurological deficits along with systemic symptoms fulfilling criteria for MS with synchronous HL. CASE PRESENTATION: A 37-year-old woman presented with bilateral extremity weakness, numbness and urinary retention, which was preceded by three weeks of night sweats, 25-pound (11 kg) weight loss and anorexia. Neurological examinations showed spastic paraparesis, sensory deficit, and a left extensor plantar response. Magnetic resonance imaging (MRI) of the brain showed multiple non-enhancing white-matter lesions, with patchy areas of peripheral gadolinium (Gd)-enhancement in the thoracic cord. Serology was positive for JC and EBV IgG antibodies. Body imaging revealed a mediastinal mass, and lymph node biopsy confirmed classical HL. Steroid infusions resulted in mild improvements in extremity weakness and numbness. She was treated with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) for HL. A Gd-enhanced MRI brain obtained after 4 cycles of ABVD showed resolution of enhancing lesions but new T2-FLAIR lesion consistent with active MS. Due to ongoing HL surveillance and concerns regarding immunosuppression, disease-modifying therapy for MS was not initiated. On her annual follow-up, she reported persistent fatigue, transient memory deficit, and residual bilateral feet numbness. DISCUSSION: The relationship between HL and MS has been explored in numerous studies, revealing an overlap in genetic susceptibility, shared biological pathways through lymphocyte-mediated immunity, JUN kinase activity, tyrosine phosphorylation, and common environmental factors, such as the presence of EBV. Our patient presented an atypical thoracic MRI finding of peripheral enhancement which led to further investigation and diagnosis of HL. The concurrent occurrence of MS and HL may point toward shared immune dysregulation.
conclusionWe report a case of co-occurrence of MS with HL and note neurological stability after treatment with ABVD chemotherapy for HL. The shared genetics and immunological interplay may explain overlaps, but MS and HL remain distinct pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.